The Upgraded Endotoxin Assay Production Facility Will Incorporate Sustainable Technologies and Streamline Manufacturing Processes
FREDERICK, Md. – Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, celebrated the start of construction for the expansion of its endotoxin assay production facility in Walkersville on September 25, 2024. Lonza is renovating approximately 18,000 square feet of dedicated manufacturing space at the site to meet growing demand for endotoxin assay products.
“Lonza’s investment in their Walkersville facility is an exciting development for Frederick County, demonstrating our region’s ability to attract and support cutting-edge biotech and manufacturing projects,” said County Executive Jessica Fitzwater. “I am excited to see how Lonza’s latest innovation will contribute to our growing biotech community.”
Lonza Walkersville manufactures the materials required to execute endotoxin assays, which are used to help ensure the safety and compliance of parenteral drugs and medical devices. Pharmaceutical companies use endotoxin assays to assess endotoxin levels in all injectable pharmaceutical products and medical devices to help ensure their safety and compliance with regulatory standards.
The investment in the facility supports Lonza’s continued drive for operational excellence. By integrating state-of-the-art automation and cutting-edge facility enhancements, the upgraded space will be tailored specifically to Lonza’s endotoxin assay product portfolio.
As part of Lonza’s continued commitment to sustainability, the renovation will incorporate environmentally friendly technologies including energy-efficient systems, waste reduction initiatives, and responsibly sourced materials, to minimize environmental impact while boosting productivity. The project will address current regulatory and market needs while anticipating future technological advancements and industry growth.
“The investment in an advanced endotoxin manufacturing facility underscores our commitment to advancing biopharmaceutical innovation while helping to ensure the highest standards of safety and quality,” said Orla Cloak, Senior Vice President, Head of Bioscience, Lonza. “Once operational, the facility will enhance our capability and capacity to meet the growing demands of the injectable drugs market, providing our customers with reliable and high-quality products that are critical for patient safety.”
Additional Information
To learn more about Lonza’s Bioscience offering, please see here: Lonza Bioscience | Lonza
Lonza Contact Details
About FCOED
The Frederick County Office of Economic Development is the central point of contact for businesses looking to start, locate, or expand in Frederick County, Maryland. We facilitate this by connecting businesses with resources at the federal, state, and local levels. Our services include assistance with site selection, workforce recruitment and training, incentives, marketing, and much more. Learn more at www.discoverfrederickmd.com .